INTRODUCTION
============

Medulloblastoma is the most occurred pediatric malignant brain tumor. Recent studies have shown significant correlations between specific polymorphisms with malignant brain tumors.^[@ref1])^ Miscellaneous studies integrating mRNA expression profile and genetic variants in medulloblastoma showed series of invaluable signature genes.^[@ref2])^ Previous studies on these signature genes such as *PTCH1*, *SUFU*, *APC*, and *TP53* indicated a significant correlation between germline gene variants as well as familiar cancer syndrome with occurrence of medulloblastoma.^[@ref3]-[@ref6])^ Northcott^[@ref7])^ reported, from a screening of the most common genes in the top list of somatic copy number aberrations (SCNAs) in 1087 unique medulloblastoma, high frequencies of SCNAs were identified in genes like *IRS2*, *PTEN*, *AKT3*, *PIK3C2B* that were enriched in the AKT signaling pathway. Further, as described by the study conducted by Wu *et al.*^[@ref8])^ on medulloblastoma mouse model, the frequency of insertions in the region of such key genes like *PTEN* and *AKT* was much higher than other background genes. Thus, genetic aberration affecting AKT signaling pathway may serve an important role in the pathogenesis of medulloblastoma.^[@ref9],\ [@ref10])^ A series of SNPs located in the region of *IRS2*, *PTEN* and *AKT3* was reported to be associated with tumor risk. Previous reports indicated a significant association between these genetic variation and the risk of breast cancer^[@ref11])^ and colorectal cancer.^[@ref12])^ The significant association of genetic polymorphism of *PTEN* with risk of esophageal squamous cell carcinoma was noted in Chinese population.^[@ref13])^ However, the association between certain SNPs in the AKT pathway with the risk, the clinical parameters and the prognosis of medulloblastoma is yet to be determined in China.

In the present case-control study, we recruited samples from 48 pediatric patients with medulloblastoma and 190 healthy adults as control in the Han population. 11 tag-SNPs in the region of *IRS2*, *PTEN*, and *AKT3* were screened through the high-throughout Sequenom MassArray genotypic approach to decipher the contribution of these SNPs in predicting the risk of susceptibility and the prognosis of medulloblastoma.

SUBJECTS AND METHODS
====================

Patients and Controls
---------------------

The study was approved by the Ethics Review Board of Shanghai Xinhua Hospital according to the Helsinki Declaration with written permission from the patients and control group. A total of 48 patients with histopathologically confirmed pediatric medulloblastoma between 2008 and 2013 were recruited from the Department of Pediatric Neurosurgery in Xinhua Hospital. Peripheral blood samples in ethylenediamine tetra acetic acid (EDTA) tubes from 190 healthy individuals with no family history of cancer in first degree relatives were recruited as controls. The control samples were appropriate for gender with the patient samples. All tumor samples were independently reviewed by two experienced pathologists and the samples were graded histologically using published criteria.1^[@ref4])^

SNP Selection and Genotyping
----------------------------

The Tag-SNPs were selected based on the following criteria: firstly based on the genes in AKT pathway with the most common somatic copy number aberrations reported previously.^[@ref7])^ Based on that, SNPs of five genes (*IRS2*, *PTENAKT3*, *PIK3C2B* and *PIK3C2G*) were selected and the pathogenic polymorphisms being associated with cancer or other diseases were screened out according to studies reported previously (http://www.ncbi.nlm.nih.gov/SNP).^[@ref15]-[@ref19])^ We finally pooled 11 tag-SNP derived from the International HapMap Project Database (http://www.hapmap.org). Minor allele frequency of each polymorphism was at least 5% in a Chinese population.

Genotypic and genetic data analyses were performed at Bio-X Institutes of Shanghai Jiao Tong University in China. Genomic DNA was supplied from peripheral blood lymphocytes of participants using the Qiagen Blood Kit (Qiagen, Basel, Switzerland). Genotypic was performed using the Sequenom MassARRAY iPLEXTM Platform (http://www.sequenom.com/seq.genotyping.html). The PCRs were carried out on the Gene Amp® PCR System 9700 (Applied Biosystems, CA, USA). The iPLEX Gold assay was detected using 10--20 ng of genomic DNA in 384-well plate format for the MassARRAY System. The quality-control analyses included the genotypic of internal positive-control samples, the use of no template controls, and replicates for 10% of the samples.

Statistical Methods
-------------------

For each polymorphism, deviation of the observed genotype frequencies from those expected under Hardy-Weinberg equilibrium (HWE) was evaluated in the Chi-square test in the SHEsis analysis platform (http://analysis.bio-x.cn/myAnalysis.php). We compared allele and genotype frequencies, Odds Ratios (ORs) and 95% confidence intervals (95% CIs) were calculated by SHEsis analyses between cases and healthy controls. The association between genotypes and the risk of medulloblastoma was analyzed by Chi-square test after stratifying the subjects according to the clinicopathological parameters. Statistical significance was set at *P*\<0.05. Survival analyses and plots were performed using PASW Statistics version 18 (SPSS Inc, Chicago, IL, USA).

RESULTS
=======

Sample Characteristic
---------------------

A group of 48 medulloblastoma patients and 190 control subjects were recruited for the present study. The mean age of the patient and control group was 4.8 years and 42.4 years (patients ranged from 0.4 to 9 years and controls varied from 22 to 58 years), respectively. The patient and control samples comprised 66.7% males and 55.8% males, respectively (*P*\>0.05). 30 (62.5%) patients had classic medulloblastoma, 5 (10.5%) cases had larger cell/anaplastic medulloblastoma, 13 (27.1%) kids were with desmoplastic medulloblastoma. In the present cohort of medulloblastoma, 19 (39.6%) were clinically listed as metastatic status, and 25 (52.1%) patients were younger than 3 years old.

Individual SNP Association Analysis
-----------------------------------

After statistical case-control analysis, carriers of four variant SNPs in *AKT3* and *IRS2* genes were linked to the risk of pediatric medulloblastoma. Allele frequency and genotype distribution of these remarkable SNPs were presented in [Table 1](#table1){ref-type="table"}. IRS2 rs7987237, rs913949 and AKT3rs897959, rs4590656 demonstrated a significant association with the risk of pediatric medulloblastoma before Boferroni corretion. Our results showed that both the allele "C "and the genotype "CC" of rs7987237 in IRS2 gene were associated with an increased risk of medulloblastoma (*P*=0.0023 and *P*=0.009, respectively). Bonferroni correction effaced most of the statistically significant association with pediatric medulloblastoma. The allele "C" of IRS2 rs7987237 still shows an increased risk (*P*=0.025; OR=2.95, 95%CI 1.43--6.11).

###### 

Genotype and Allele Frequencies of Significant SNPs in the patient-control Analysis.

                              Allele            Odds Ratio OR                                          HWB-*P*           
  ------------ -------------- -------- -------- ------------------- ------- -------- -------- -------- --------- ------- -----------
  rs7987237    *IRS2*         C        T                                             C/C      C/T      T/T               
               case/control   87/291   9/89     2.95 (1.43--6.11)   0.002   0.025    39/111   9/69     0/10      0.009   0.47/0.86
  rs913949     *IRS2*         A        G                                             A/A      A/G      G/G               
               case/control   81/279   13/101   2.25 (1.20--4.22)   0.009   \>0.05   34/90    13/99    0/1       0.008   0.27/0.07
  rs4590656    *AKT3*         C        T                                             C/C      C/T      T/T               
               case/control   69/215   25/153   1.96 (1.18--3.24)   0.007   \>0.05   26/67    17/81    4/36      0.038   0.61/0.20
  rs897959     *AKT3*         C        T                                             C/C      C/T      T/T               
               case/control   68/225   24/147   1.85 (1.11--3.08)   0.016   \>0.05   28/74    12/77    6/35      0.035   0.02/0.06
  rs2735343    *PTEN*         C        G                                             C/C      C/G      G/G               
               case/control   44/183   50/197   --                  0.8     --       10/40    24/103   13/47     0.9     --
  rs2248293    *PTEN*         C        T                                             C/C      C/T      T/T               
               case/control   40/174   42/184   --                  0.9     --       12/43    16/88    13/48     0.5     --
  rs12357281   *PTEN*         G        --                                            G/G                                 
               case/control   94/380   --       --                  1       --       47/190                      1       --
  rs4773092    *IRS2*         A        C                                             A/A      A/G      G/G               
               case/control   51/235   43/145   --                  0.17    --       14/68    23/99    10/23     0.25    --
  rs2289046    *IRS2*         A        G                                             A/A      A/G      G/G               
               case/control   46/218   48/156   --                  0.10    --       11/65    24/88    12/34     0.26    --
  rs754204     *IRS2*         C        T                                             C/C      C/T      T/T               
               case/control   59/246   37/130   --                  0.46    --       17/81    25/84    6/23      0.6     --
  rs4132509    *AKT3*         A        C                                             A/A      A/C      A/A       C/C     
               case/control   39/124   55/256   --                  0.10    --       10/22    19/80    18/88     0.2     --

Global chi2 is 94.65 while df=15 (frequency\<0.03 in both control & case has been dropped.) Global Fisher's *p* value is 1.90e--013; Global Pearson's *p* value is 1.33e--013. *P*\*: Boferroni correction *P* value; HWB-*P*: *P* value of Hardy-Weinberg equilibrium for the patients and control population.

Genotype SNP and Clinicopathological Parameters of Medulloblastoma
------------------------------------------------------------------

In these children with medulloblastoma, genotype of significant rs7987237 might affect clinical parameter of medulloblastoma such as pathological diagnosis, metastatic status, age of onset. As showed in [Table 2](#table2){ref-type="table"} the clinicopathological parameters of patients displayed significant differences between various genotype groups of rs7987237 (*P*\<0.05). Furthermore, we described different survival curve for various genotype of rs7987237 in Kaplan-Meier analysis. The significant difference was found in [Figure 1](#fig1){ref-type="fig"} (*P*\<0.001).

###### 

Correlation between SNP genotypes of IRS2 and clinicopathological parameters of medulloblastoma patients

  Variable                                        rs7987237   rs913949                         
  ----------------------- ----------------------- ----------- ---------- ----------- ---- ---- ------
  Age group               ≤3years                 25          5          0.63        19   10   0.37
                          \>3years                14          4                      14   4    
  Gender                  Female                  15          4          0.74        12   6    0.67
                          Male                    24          5                      21   8    
  Histological type       Classic                 25          5          **0.02**    19   10   0.06
                          Desmoplastic            12          1                      12   1    
                          Large cell/Anaplastic   2           3                      2    3    
  Metastatic risk group   M0                      27          2          **0.006**   22   7    0.28
                          M1-3                    12          7                      11   7    

*P* values obtain using χ2 or Fisher's exact tests.

![Different survival curve for various genotype of rs7987237 in Kaplan-Meier analysis](2186-3326-79-0047-g001){#fig1}

DISCUSSION
==========

In the current study, we identified novel SNPs of susceptibility genes like *AKT*, *IRS2* and their correlation with clinic-pathological parameters from the case-control study consisting of 48 medulloblastoma patients matched with 190 controls. Our findings suggest that rs7987237 may harbor association with clinical parameters of pediatric medulloblastoma, such as tendency to metastasis, clinical prognosis. This is the first study showing this association with pediatric medulloblastoma in the Han Chinese population.

The IRS-AKT pathway has turned out to be aberrantly activated in malignant brain tumors.^[@ref20])^ Elizabeth identifies *IRS2* as a driver oncogene and *IRS2* activated by PI3K-AKT pathway may represent an optional mechanism in the process of carcinogenesis.^[@ref21])^ It is equally a vital mediator triggering tumor metastasis^[@ref22])^ and affected clinical prognosis.^[@ref23])^ The association between polymorphic changes of *IRS2* with pediatric medulloblastoma has yet to be unclear. Diverse teams provided evidences that the insulin-like growth factor may contribute to medulloblastoma transformation.^24,25)^ In our present results, the difference of genotype and allele frequencies of rs7987237 in *IRS2* between the case and control groups revealed a significant association with medulloblastoma susceptibility. Polymorphisms of *IRS2* correlated with the severity of breast cancer^[@ref26])^ and the clinical outcome in pancreatic cancer.^[@ref27])^ Feigelson HS genotyped 648 cases of cancers and 659 controls finding that some SNPs in *IRS2* regions may harbor risk alleles for breast cancer ([Table 3](#table3){ref-type="table"}).^[@ref11])^ Combining with those previous investigations, our study suggests a potential role of polymorphisms of *IRS2* in the development of pediatric medulloblastoma. Although, the functional aspect of polymorphisms of *IRS2* still requires further investigation.

###### 

Summary of the significant SNPs in the present study and in previous literature.

  ---------------------------------------------------------------------------------------------------------------------
           in the present study   in previous study                                               
  -------- ---------------------- ------------------- ------------- ------------------------ ---- ---------------------
  *IRS2*   rs7987237              \+                  0.002/0.009   Breast cancer            \+   Feigelson HS (2008)

  *AKT3*   rs4590656              \+                  0.007/0.035   High altitude\           \+   Buroker NE (2012)
                                                                    sickness                      

  *AKT3*   rs897959               \+                  0.016/0.038   Diabete Mellitus type2   \+   Sookoian S (2009)
  ---------------------------------------------------------------------------------------------------------------------

On the other hand, the polymorphism impact of *IRS2* may be covered beneath the clinical manifestations. Present study further explored possible clue between genotype of rs2987237 and patients' clinical phenotype the pathological characteristics of pediatric medulloblastoma. In the present cohort, the incidence of medulloblastoma metastasis including M1-M3 was 39.58% (19/48), which is the same as 40% as reported by previous reports.^[@ref8])^ Clinicopathological variables may portend high risk of poor prognosis in addition to larger cell/anaplastic histology. Half of patients are under the age of 3 years old (24/48), which is slightly higher than previously reported studies.^[@ref28])^ 60% of patients in our study were confirmed to be classic histology (29/48). In the present study, the genotype C/T of rs7987237 in patients shown closer association with larger cell/ anaplastic medulloblastoma and the risk of metastatic, both of which increased the likelihood of a poor prognosis. Furthermore, Kaplan-Meier survival curve of these patients with the genotype C/T of rs7987237 showed significantly poorer overall survival than genotype C/C. These results suggest polymorphism of rs7987237 could serve as a useful bio-marker predicting the risk of metastasis and clinical outcome.

Although this is the first study focusing on SNP of *IRS2* involved in the pediatric medulloblastoma susceptibility and clinical parameters in the Han Chinese population, the number of patients was limited. Future study would definitely incorporate larger population which is essential for addressing a definitive conclusion of certain germline polymorphisms. The exact function of the polymorphisms and regulatory mechanism for gene expression has not meant to research clearly. The molecular mechanisms still have yet to be investigated in detail.

CONCLUSIONS
===========

Our finding suggests that the polymorphisms of *IRS2* has a potential role in the development of pediatric medulloblastoma. Furthermore, they may also correlate with the clinicopathologic feature of medulloblastoma which may suggest a putatively functional involvement of *IRS2* polymorphisms in the pathogenesis of medulloblastma. As a novel liquid biopsy approach, the germ line variants of *IRS2* status may be helpful in aiding the diagnosis and predicting the prognosis of medulloblastoma in a minimal invasive way. It would also shed light in the forthcoming investigation in deciphering the contribution of germ line variants to the etiology of medulloblastoma.
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